{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:59:02Z","timestamp":1785218342783,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of a single-test, targeted DNA next-generation sequencing (NGS) panel in classifying endometrial carcinoma (EC) into molecular subtypes and to compare its performance with that of the established Sanger sequencing + immunohistochemistry (Sanger + IHC) molecular classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Targeted DNA NGS was performed on 131 samples using the clinically validated AmoyDx\u00ae Comprehensive Panel, and a commercially available targeted AmoyDx EC Panel covering POLE, TP53, and MSI was used for 63 samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The concordance between the NGS and Sanger + IHC classifications was 93.8% (182\/194 cases), with a kappa value of 0.908. The exclusion of seven discordant\n                      <jats:italic>POLE<\/jats:italic>\n                      mutations improved concordance to 97.4% (kappa = 0.962). NGS identified 30\n                      <jats:italic>POLE<\/jats:italic>\n                      mutations compared to 23 detected by Sanger sequencing, which missed low-frequency variants. Microsatellite instability (MSI) analysis and mismatch repair (MMR) immunohistochemistry (IHC) results were highly concordant (97.9%). However, NGS-based\n                      <jats:italic>TP53<\/jats:italic>\n                      mutation detection showed moderate agreement with the p53 IHC results (kappa = 0.688). Mutations associated with targeted therapy trials, including PTEN (76.3%), PIK3CA (50.4%), and ARID1A (35.9%), were found in 131\u00a0EC samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that NGS-based molecular classification aligns well with Sanger + IHC molecular classification and offers higher sensitivity than Sanger sequencing, thereby improving the identification of mutations associated with targeted therapy trials. This enhances the prognosis and treatment planning for patients with advanced EC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/pore.2026.1612465","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:10:05Z","timestamp":1785215405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes"],"prefix":"10.3389","volume":"32","author":[{"given":"Lingfeng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"You","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunbin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejogrb.2021.11.423","article-title":"British gynaecological cancer society (bgcs) uterine cancer guidelines: recommendations for practice","volume":"270","author":"Morrison","year":"2022","journal-title":"Eur Journal Obstetrics, Gynecology, Reproductive Biology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a transportec initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the promise molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/his.13977","article-title":"Revising the who classification: female genital tract tumours","volume":"76","author":"Cree","year":"2020","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101839","DOI":"10.1136\/ijgc-2024-006160","article-title":"Streamlined approach to endometrial cancer: figo 2023 staging","volume":"35","author":"Grosse","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'Multiple-Classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"155152","DOI":"10.1016\/j.prp.2024.155152","article-title":"Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population","volume":"254","author":"Kang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.humpath.2021.02.006","article-title":"Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and proactive molecular risk classifier for endometrial cancer classifier","volume":"111","author":"Huvila","year":"2021","journal-title":"Hum Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"935694","DOI":"10.3389\/fonc.2022.935694","article-title":"Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1002\/cpmb.59","article-title":"Overview of next-generation sequencing technologies","volume":"122","author":"Slatko","year":"2018","journal-title":"Curr Protoc Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.5375","article-title":"P53 immunohistochemistry is an accurate surrogate for Tp53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/pgp.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.Ccr-15-2233","article-title":"Endometrial carcinomas with pole exonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic pole mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"B17","first-page":"2017","article-title":"Oncokb: A Precision Oncology Knowledge Base","volume-title":"JCO Precision Oncol","author":"Chakravarty","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.20980","article-title":"Parallel sequencing used in detection of mosaic mutations: Comparison with four diagnostic DNA screening techniques","volume":"30","author":"Rohlin","year":"2009","journal-title":"Hum Mutat"},{"key":"B20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ygyno.2015.01.541","article-title":"Detection of DNA mismatch repair (mmr) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (msi) phenotype in endometrial carcinomas","volume":"137","author":"McConechy","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24054866","article-title":"Diagnostic performance of immunohistochemistry compared to molecular techniques for microsatellite instability and P53 mutation detection in endometrial cancer","volume":"24","author":"Streel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12880","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"P53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the Portec-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/jco.2017.72.7107","article-title":"Phosphatidylinositol 3-Kinase \u0391-Selective inhibition with alpelisib (Byl719) in Pik3ca-Altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cncr.32677","article-title":"Phase 2 study of Ly3023414 in patients with advanced endometrial cancer harboring activating mutations in the Pi3k pathway","volume":"126","author":"Rubinstein","year":"2020","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/s41416-020-01041-x","article-title":"Phase 1 study of Mtorc1\/2 inhibitor sapanisertib (Tak-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","volume":"123","author":"Voss","year":"2020","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, nccn Clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/gco.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (Her2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ygyno.2020.06.509","article-title":"Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: changes in diagnoses and mutational frequency over 20 years","volume":"159","author":"Weiss","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41379-018-0055-1","article-title":"Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a transportec initiative","volume":"31","author":"Auguste","year":"2018","journal-title":"Mod Pathol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41416-023-02203-3","article-title":"Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer","volume":"128","author":"Asami","year":"2023","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"Ctnnb1 (Beta-Catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:10:07Z","timestamp":1785215407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":33,"alternative-id":["10.3389\/pore.2026.1612465"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612465","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1612465"}}